Research digest / Safety & tolerability
Sermorelin is a GHRH(1-29) growth-hormone secretagogue, read here through what the safety and tolerability data report.
A premium digest of the mechanism, the pharmacology, and the reported effects for a peptide that was approved, withdrawn for commercial reasons, and is now compounded — every quantitative claim carried back to its study.
The short version
Sermorelin is a lab-made copy of the first 29 building blocks of a natural brain hormone (GHRH) that tells the pituitary gland to release the body's own growth hormone. It does not add growth hormone from outside; it nudges the gland to make its own, in the natural on-off rhythm. It was once an approved medicine for short children, was pulled from the US market in 2008 for business reasons (not safety), and is now made to order by compounding pharmacies. Studies report mostly mild, dose- and route-dependent effects, but long-term data in adults are genuinely thin. This page summarizes that record plainly and cites every number.
What the sermorelin literature establishes
Sermorelin (sermorelin acetate) is a synthetic, amidated 29-amino-acid peptide — the GHRH(1-29) fragment of growth-hormone-releasing hormone, the shortest piece that keeps full activity at the GHRH receptor (the docking site on the pituitary that growth-hormone-releasing hormone normally binds) [1]. It works by telling the pituitary gland to release the body's own growth hormone (GH), rather than supplying GH from outside. Because it acts upstream, the body's natural brakes stay in place: somatostatin (the hypothalamic hormone that switches GH release off) and IGF-1 feedback continue to regulate the pulse [4].
The quantitative record is consistent where it has been measured. In growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without overshooting IGF-1 (insulin-like growth factor 1, the liver-made hormone that carries out most of GH's effects) [2]. In healthy older men, 0.5 mg and 1 mg twice daily for 14 days produced dose-related rises in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 numbers no longer differed from young men, with no change in fasting glucose [3]. In 30 healthy men, intravenous GHRH(1-29)NH2 triggered GH release at doses as low as 0.25 mcg/kg [5].
What the literature does not establish is just as important to state. Authorities have judged growth-hormone-secretagogue use to slow or reverse aging "not yet ready for prime time" [6], and a 2025 Nature Reviews Endocrinology review frames GHRH-analogue therapy as an active, still-resolving field rather than a settled one [9]. The honest reading is a precise short-term pharmacology paired with limited long-term adult data.
What is sermorelin?
What is sermorelin? Sermorelin is a synthetic, amidated 29-amino-acid peptide corresponding to the GHRH(1-29) fragment of growth-hormone-releasing hormone — the shortest fragment that retains full GHRH-receptor activity — studied as a pituitary growth-hormone secretagogue (a substance that prompts the pituitary to release growth hormone) [1].
What does sermorelin do to the body? It binds GHRH receptors on anterior-pituitary somatotrophs (the GH-producing cells), activating the cAMP/PKA pathway (an internal cell-signaling cascade) to stimulate synthesis and pulsatile release of the body's own growth hormone and, downstream, hepatic IGF-1 — while somatostatin and IGF-1 feedback remain intact [1][4].
What is sermorelin used for? Sermorelin was FDA-approved for evaluating and treating growth-hormone deficiency and short stature in children, and has been studied in research on the aging GH/IGF-1 axis, body composition, sleep, and cognition [2][3]. It was withdrawn from the US market in 2008 for commercial reasons, is now prepared by compounding pharmacies, and is summarized here as a research peptide for laboratory study.
Sermorelin acetate: identity and chemistry
Sermorelin acetate is the acetate salt of the GHRH(1-29) peptide. Its molecular weight is 3357.9 Da and its molecular formula is C149H246N44O42S; the free-peptide CAS number is 86168-78-7 [1]. It is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions degrade, and it is reconstituted with sterile diluent before study use [10].
As a research peptide, GHRH(1-29) is the active core of a 44-residue hypothalamic hormone — nature's own GH-release signal, cut down to its essential 29 amino acids. That compactness is the whole identity: it is the shortest fragment that still fully engages the GHRH receptor, which is why it became the basis for an approved drug and for the longer-acting analogues that followed.
Sermorelin as a research peptide
As a sermorelin peptide preparation, GHRH(1-29)NH2 is studied for its defining action: pituitary GH secretagogue activity through the body's own feedback-regulated machinery. Its appeal in the GH-axis literature is that it preserves the natural pulsatile pattern of secretion rather than flooding the system with exogenous hormone [4].
The peptide's identifiers anchor it precisely: GHRH(1-29) / GRF(1-29) shorthand, MW 3357.9 Da, CAS 86168-78-7, PubChem CID 16132413 [1]. Its short native half-life — on the order of 10-12 minutes after intravenous dosing — is the single most consequential pharmacologic fact about it, and the reason longer-acting GHRH analogues were engineered; see sermorelin half-life and pharmacokinetics [5].
Mechanism: how GHRH(1-29) engages the pituitary GHRH receptor
Sermorelin reproduces the action of natural growth-hormone-releasing hormone. It binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor (a membrane sensor that converts an outside signal into an inside one) on pituitary somatotrophs, switching on Gs / adenylate cyclase / cAMP / protein kinase A signaling [1]. That cascade drives GH gene transcription and a trophic, somatotroph-supporting effect, then a pulse of GH release [1].
Downstream, GH prompts the liver to make IGF-1, the hormone that carries out most of GH's effects and also feeds back to dampen further GH release [1]. Because sermorelin acts upstream on the pituitary rather than supplying GH directly, somatostatin and IGF-1 feedback stay intact — an editorial argued this physiologic, feedback-preserving approach may suit adult-onset GH insufficiency better than recombinant GH [7]. The full cascade is detailed in the aging GH/IGF-1 axis research.